Form 8-K - Current report:
SEC Accession No. 0001213900-20-043105
Filing Date
2020-12-17
Accepted
2020-12-16 17:34:18
Documents
6
Period of Report
2020-12-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea131766-8k_immucellcorp.htm 8-K 29221
2 TERM NOTE FOR $1,500,000 EXECUTED BY IMMUCELL CORPORATION IN FAVOR OF GORHAM SAV ea131766ex10-1_immucell.htm EX-10.1 56418
3 LOAN AGREEMENT FOR $1,500,000 EXECUTED BY IMMUCELL CORPORATION IN FAVOR OF GORHA ea131766ex10-2_immucell.htm EX-10.2 99865
4 PRESS RELEASE OF IMMUCELL CORPORATION DATED DECEMBER 15, 2020. ea131766ex99-1_immucell.htm EX-99.1 14027
5 GRAPHIC ex10-1_001.jpg GRAPHIC 7650
6 GRAPHIC ex10-2_001.jpg GRAPHIC 7650
  Complete submission text file 0001213900-20-043105.txt   222099
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 201393458
SIC: 2835 In Vitro & In Vivo Diagnostic Substances